Today: 9 June 2026
Browse Category

NASDAQ:BIIB 25 August 2025 - 21 May 2026

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Apellis Stock Disappears From Nasdaq as Biogen $41 Billion Buyout Faces Final Hurdle

Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, ending APLS trading on Nasdaq as of May 15. Former Apellis shareholders receive $41 per share in cash and a contingent value right tied to future Syfovre sales. Biogen shares rose 0.6% early Thursday. The CVR pays only if Syfovre meets specific sales milestones; there is no guarantee of payout.
21 May 2026
···
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Biogen completed its acquisition of Apellis Pharmaceuticals, removing APLS shares from Nasdaq and paying investors $41 per share plus a contingent value right tied to Syfovre sales. Apellis shareholders tendered 82.4% of outstanding stock before the offer expired May 13. Biogen shares rose 0.9% to $192.34 Wednesday. The CVR could pay up to $4 if Syfovre meets future sales targets.
20 May 2026
····
Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Apellis Exits Nasdaq; $41 Takeover Wraps, One Bet Left

Biogen completed its acquisition of Apellis Pharmaceuticals last week, delisting Apellis from Nasdaq after accepting 82.4% of shares in a $41-per-share cash deal plus a contingent value right. Apellis became a Biogen subsidiary on May 14. The CVR will pay holders up to $4 if Syfovre sales meet specified targets. Biogen shares closed at $192.95 on Friday.
17 May 2026
··
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen has closed its acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and delisting its shares from Nasdaq. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains the drugs Empaveli and Syfovre, and expands into kidney disease. Biogen borrowed $2 billion to help finance the deal.
15 May 2026
···
Why Nvidia, Cisco, Cerebras, Boeing and Biogen Are the US Stocks to Watch Today

Why Nvidia, Cisco, Cerebras, Boeing and Biogen Are the US Stocks to Watch Today

Cisco will cut nearly 4,000 jobs and raised its annual revenue forecast after AI infrastructure orders hit $5.3 billion. Nvidia shares remain sensitive to U.S.-China chip policy after U.S. officials cleared Chinese firms to buy H200 processors, though no shipments have occurred. Cerebras debuted with a $5.55 billion IPO, opening at $350 per share. Boeing shares fell after China pledged to buy 200 jets, fewer than expected.
15 May 2026
······
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
14 May 2026
···
Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Biogen agreed to buy Apellis Pharmaceuticals for $5.6 billion, offering $41 per share in cash plus sales-based rights tied to the eye drug Syfovre. Apellis shares traded at $40.23 after the announcement. The deal includes a contingent value right worth up to $4 if Syfovre hits certain sales milestones. Apellis’ board and key shareholders, holding 14%, backed the offer, which is expected to close in the second quarter.
1 April 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts

Biogen shares traded near $175 on Dec. 22 as the company announced JAMA Neurology published final long-term results from its Phase 3 VALOR study of QALSODY for SOD1-ALS. The stock was removed from the Nasdaq-100 index today, following a surge in volume last Friday. Analyst ratings remain mixed, with price targets ranging from the low-$140s to above $200.
22 December 2025
·
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split

Biogen shares closed at $174.80 on Dec. 19, up 2.88% with trading volume spiking to 15 million shares, well above the 50-day average. The stock remains about 5% below its 52-week high of $185.17. Recent filings show new institutional positions from Wedge Capital Management and Fluent Financial. Leqembi was added to China’s Commercial Insurance Innovative Drug List, effective Jan. 1, 2026.
21 December 2025
··
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open

Biogen shares closed up 2.88% at $174.80 Friday, with trading volume surging to about 15 million shares, far above the 50-day average. The move followed bullish analyst commentary from RBC Capital, which reiterated an “Outperform” rating and a $210 price target. After-hours, BIIB edged higher to $176.23. Renewed focus on Alzheimer’s treatments and pipeline prospects drove activity.
20 December 2025
·
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen shares hit a 52-week high Monday, closing at $177.42, up 1.2%, after Novo Nordisk’s Alzheimer’s drug failed in late-stage trials. The stock traded as high as $185.17 intraday on volume of about 2.07 million shares. Investors also reacted to Biogen’s new immunology partnership with Dayra Therapeutics. Novo shares fell sharply on the trial news.
24 November 2025
··
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen shares fell about 2.6% after hours Oct. 30 following Q3 results that beat estimates, with revenue at $2.53 billion and adjusted EPS of $4.81. The company cut 2025 non-GAAP EPS guidance to $14.50–$15.00, citing a $1.25 per-share R&D charge. Leqembi sales reached $121 million, up 80% year-over-year. Biogen licensed Vanqua Bio’s inflammation drug for up to $1.06 billion.
30 October 2025
··
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Researchers used AI to design the first viruses from scratch, creating bacteriophages that killed drug-resistant bacteria. Scientists solved why smoking affects ulcerative colitis and Crohn’s disease differently, linking it to mouth bacteria. New Alzheimer’s drugs modestly slowed disease in early stages. Wildfire smoke could kill 70,000 Americans annually by 2050, Stanford researchers warned.
20 September 2025
·····
FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······

Stock Market Today

  • Elon Musk Says SpaceX Can Set Up AI Data Centers in Space Without 'Magic'
    June 8, 2026, 7:24 PM EDT. Elon Musk stated that deploying artificial intelligence (AI) data centers in orbit is not a "super hard problem," disputing critics who view orbital data centers as highly challenging. Musk's SpaceX aims to leverage space infrastructure to host AI computing facilities, emphasizing practical solutions over technological impossibility.

Latest articles

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

Mingteng Stock Jumps 81% After Halting $100M Share Sale Plan

9 June 2026
Mingteng International shares soared 81.3% to $1.94 after the company ended its at-the-market stock sale plan, having raised about $20.6 million in gross proceeds; trading volume hit 24.2 million, dwarfing its $12 million market value, as the move outpaced gains in other U.S.-listed China auto stocks.
Peso Rebounds, But Mexico’s Next Inflation Print Looms

Peso Rebounds, But Mexico’s Next Inflation Print Looms

9 June 2026
Mexico’s peso edged up 0.09% to 17.4644 per dollar after Iran and Israel paused attacks, but traders turned cautious ahead of Tuesday’s Mexico inflation data, which could shape Banxico rate expectations and impact the peso’s yield advantage that has supported the currency.
T1 Energy Shares Dip After KORE Power Files New Update

T1 Energy Shares Dip After KORE Power Files New Update

9 June 2026
T1 Energy shares slid 3.2% to $9.13 after a new SEC filing revealed up to $24.7 million in stock-linked payments for its $32 million KORE Power acquisition, spotlighting dilution risks as the company expands into battery storage and data-center power; the deal’s structure and timing come as T1 seeks growth funding and investors weigh near-term costs against future EBITDA targets.
OpenAI IPO filing puts AI rally at center stage for Wall Street

OpenAI IPO filing puts AI rally at center stage for Wall Street

9 June 2026
OpenAI has confidentially filed for a possible IPO, but investors won’t see key financials—including revenue quality, cash burn, and compute costs—until the S-1 goes public; with $2 billion monthly revenue and a recent $852 billion valuation, the filing signals a pivotal shift as AI giants race for public capital amid rising infrastructure costs and growing competition from Anthropic.
Go toTop